Table 1 Demographics and Results.
Total Sample | Responders | Non-responders | Comparing Response Groups | ||
|---|---|---|---|---|---|
t | (p) | ||||
Demographics | |||||
(n.) | 25 | 15 | 10 | ||
Sex | |||||
Male | 6 | 3 | 3 | ||
Female | 19 | 12 | 7 | ||
Age (range in years) | 47.4 (19–72) | 42.93 (29–68) | 53.20 (29–72) | 1.68 | 0.106 |
Clinical Information | |||||
HDRS-17 | |||||
Baseline (±sd) | 24.28 (±3.86) | 25.27 (±4.50) | 22.80 (±2.04) | −1.857 | 0.078 |
Post-treatment (±sd) | 14.36 (±6.65) | 9.67 (±2.77) | 21.40 (±3.78) | 8.977 | <0.0001 |
Change (±sd) | 9.92 (±8.34) | 15.60 (±4.75) | 1.40 (±3.98) | −7.795 | <0.0001 |
Age at Onset (range in years) | 29.83 (11–62) | 26.29 (13–62) | 35.33 (11–60) | ||
Recurrence | |||||
Single Episode | 1 | 0 | 1 | ||
Recurrent | 24 | 15 | 9 | ||
Severity | |||||
mild | 0 | 0 | 0 | ||
moderate | 11 | 6 | 5 | ||
severe w/o psychotic f. | 10 | 7 | 3 | ||
unknown | 4 | 2 | 2 | ||
Medications | |||||
antidepressant | 22 | 12 | 10 | ||
mood stabilizer | 0 | 0 | 0 | ||
benzodiazepine | 8 | 4 | 4 | ||
antipsychotic | 8 | 6 | 2 | ||
stimulant | 3 | 1 | 2 | ||
no psychotropic medication | 2 | 2 | 0 | ||
Psychiatric Comorbidities | |||||
Dysthymic Disorder | 2 | 0 | 2 | ||
Axis II Diagnosis | 1 | 1 | 0 | ||
Anxiety Disorders | 9 | 6 | 3 | ||
Other | 1 | 1 | 0 | ||
None | 13 | 8 | 5 | ||
Physical Comorbidities | |||||
Endocrine | 6 | 4 | 2 | ||
Musculoskeletal/Pain | 4 | 3 | 1 | ||
Cardiovascular | 2 | 0 | 2 | ||
Other | 6 | 4 | 2 | ||
None | 10 | 7 | 3 | ||
ECT Information | |||||
Number of treatments (range) | 13.60 (8–29) | 12.13 (8–21) | 15.80 (9–29) | ||
Seizure Threshold (mC) (±sd) | 26.18 (±10.76) | 22.40 (±10.30) | 30.72 (±9.91) | ||
Seizure Duration (seconds) | |||||
Observed physical (±sd) | 40.67 (±15.19) | 44.29 (±15.73) | 35.60 (±13.55) | — | — |
Observed EEG (±sd) | 54.87 (±21.44) | 56.21 (±19.18) | 53.10 (±25.26) | — | — |
Neurophysiology | |||||
RMT (%) | |||||
Baseline (±sd) | 48.25 (±10.36) | — | — | — | — |
Post-treatment (±sd) | 45.84 (±7.79) | — | — | — | — |
Change (±sd) | −3.00 (±8.20) | — | — | — | — |
Cortical Silent Period (ms) | |||||
Baseline (±sd) | 136.50 (±31.88) | 126.12 (±24.26) | 152.07 (±36.70) | 2.136 | 0.044 |
Post-treatment (±sd) | 141.98 (±37.44) | 142.33 (±39.39) | 141.46 (±36.40) | −0.055 | 0.956 |
Change (±sd) | 5.48 (±41.33) | 16.20 (±42.83) | −10.60 (±34.96) | −1.644 | 0.114 |
SICI (%) | |||||
Baseline (±sd) | 70.37 (±37.19) | 64.80 (±39.91) | 78.71 (±32.88) | 0.913 | 0.371 |
Post-treatment (±sd) | 80.20 (±45.52) | 76.50 (±48.02) | 85.74 (±43.37) | 0.489 | 0.629 |
Change (±sd) | 9.83 (±49.09) | 11.70 (±44.04) | 7.03 (±58.26) | −0.228 | 0.821 |
